4-Amino-3-methyl-valeriansaeure | 89584-35-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Amino-3-methyl-valeriansaeure
• 英文别名: 4-Amino-3-methylpentanoic acid
• CAS: 89584-35-0
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: CGHPFTQVVBLEBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4,5-dimethyl-2-pyrrolidone 在 盐酸 作用下， 生成 4-Amino-3-methyl-valeriansaeure
  参考文献：
  名称：

  Colonge,J.; Pouchol,J.-M., Bulletin de la Societe Chimique de France, 1962, p. 598 - 603

  摘要：

  DOI：

文献信息

• BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME
  申请人：Sibi Mukund P.

  公开号：US20110218342A1

  公开（公告）日：2011-09-08

  Disclosed are β-amino acids that are unsubstituted in the β position; that are substituted in the β position with an aryl group; that are substituted in the α position with an aryl group; that bear two substituents in the α position; and/or that are substituted in the α and β positions with groups which, together with the carbon atoms at the α and β positions, form a ring. Also disclosed are methods for making the above-mentioned β-amino acids and other β-amino acids which involve providing an α,β-unsaturated imide; converting the α,β-unsaturated imide to a 2-substituted-isoxazolidin-5-one; and converting the 2-substituted-isoxazolidin-5-one to a β-amino acid.

  披露了未在β位取代的β-氨基酸；在β位用芳基取代的β-氨基酸；在α位用芳基取代的β-氨基酸；在α位带有两个取代基的β-氨基酸；和/或在α和β位用与α和β位的碳原子一起形成环的基团取代的β-氨基酸。还披露了制备上述β-氨基酸和其他β-氨基酸的方法，包括提供α，β-不饱和亚胺；将α，β-不饱和亚胺转化为2-取代异噁唑啉-5-酮；将2-取代异噁唑啉-5-酮转化为β-氨基酸。
• [EN] ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162293A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够与靶标结合的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的应用。
• [EN] IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS DE L'IGF-1R-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162291A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

  本发明涉及一种能够结合IGF-1R的抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够结合IGF-1R的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的方法。
• [EN] CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ DE MONOMÉTHYLE AURISTATINE F ET DE TRASTUZUMAB ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2016173682A1

  公开（公告）日：2016-11-03

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括由曲妥珠单抗组成的抗体，所述抗体与至少一种由单甲基奥瑞他汀F衍生物组成的药物偶联。该发明还包括治疗方法和使用所述抗体药物偶联物治疗癌症的方法。
• [EN] DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS<br/>[FR] DÉRIVÉS DE DOLASTATINE 10 ET D'AURISTATINES
  申请人：PF MEDICAMENT

  公开号：WO2014174062A1

  公开（公告）日：2014-10-30

  The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.

  本发明涉及以下式(I)的化合物，其中：- R1为H或OH，- R2为(C1-C6)烷基，COOH，COO-((C1-C6)烷基)或噻唑基，- R3为H或(C1-C6)烷基，- R4为：- 被OH和NR9R10基之一或多个基团取代的芳基-(C1-C8)烷基，或- 可选择地被(C1-C6)烷基，OH和NR12R13基团之一或多个基团取代的杂环-(C1-C8)烷基，或其药学上可接受的盐、水合物或溶剂化合物，以及其在特定用途中，特别是用于治疗癌症的用途，含有相同化合物的药物组合物以及其制备方法。